Emistat FT 4 mg (Flash Tablet)
Unit Price: ৳ 6.00 (3 x 10: ৳ 180.00)
Strip Price: ৳ 60.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ondansetron |
| Company | Healthcare pharmaceuticals ltd |
| Also available as |
Indications
- Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy
- Prevention and treatment of post-operative nausea and vomiting
- Prevention of radiotherapy-induced nausea and vomiting
Dosage
- Variety of dosages for chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and postoperative nausea and vomiting for adults, pediatric patients, and geriatric patients
- Different dosage forms: tablet, orodispersible tablet, injection, and oral solution
Pharmacology
- Ondansetron is a potent, highly selective 5HT3 receptor-antagonist
- Exact mode of action in the control of nausea and vomiting is not known
- Blocks the initiation of vomiting reflex by activating vagal afferents via 5HT3 receptors
- Probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system
Administration
- Instructions for administering the oral soluble film: tear the pouch, place film on top of the tongue, dissolve within 20 seconds, swallow with saliva, wash hands after taking the film
Interaction
- Emistat FT does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver
- May be metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, thus interactions may occur with inducers or inhibitors of these enzymes
Contraindications
- Contraindicated in patients known to have hypersensitivity to the drug or any of its components
- Concomitant use of apomorphine
Side Effects
- Frequently reported adverse events such as headache, constipation, and diarrhea
- Rare cases of anaphylaxis, bronchospasm, tachycardia, angina, hypokalemia, shortness of breath
- No evidence of extrapyramidal reactions
- Rates of adverse events not significantly different in the Emistat FT and placebo groups
Pregnancy & Lactation
- Carcinogenic effects not seen in 2-year animal studies
- Ondansetron not mutagenic or affecting fertility in animals
- No adequate and well-controlled studies in pregnant women
- Excreted in the breast milk of rats, caution should be exercised when administered to nursing women
Precautions & Warnings
- Hypersensitivity reactions reported in patients hypersensitive to other 5-HT3 receptor antagonists
- Not a drug that stimulates gastric or intestinal peristalsis
- Should not be used instead of nasogastric suction
- May mask a progressive ileus and/or gastric distension in certain patients
Use in Special Populations
- Dosage adjustments for patients with impaired renal function and severe hepatic impairment
- Limited information available about dosage in pediatric patients 4 years of age or younger
- No dosage adjustment needed in patients over the age of 65
Therapeutic Class
Anti-emetic drugs
Storage Conditions
Store at temperature not exceeding 30°C in a dry place, protect from light and moisture